A novel approach of water-soluble paclitaxel prodrug with no auxiliary and no byproduct: Design and synthesis of isotaxel

Journal of Medicinal Chemistry

Volumn 46, Issue 18, 2003, Pages 3782-3784

  Hayashi, Yoshio ^a   Skwarczynski, Mariusz ^a   Hamada, Yoshio ^a   Sohma, Youhei ^a   Kimura, Tooru ^a   Kiso, Yoshiaki ^a  

^a KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ISOTAXEL; NATURAL PRODUCT; PACLITAXEL; PRODRUG; UNCLASSIFIED DRUG;

AQUEOUS SOLUTION; ARTICLE; DRUG DESIGN; DRUG ELIMINATION; DRUG METABOLISM; DRUG TARGETING; HYDROPHILICITY; HYPERSENSITIVITY REACTION; MOLECULAR INTERACTION; SOLUBILIZATION; STEREOCHEMISTRY; SYNTHESIS;

ANTINEOPLASTIC AGENTS; HYDROGEN-ION CONCENTRATION; KINETICS; PACLITAXEL; PRODRUGS; SOLUBILITY; WATER;

EID: 0041919716     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm034112n     Document Type: Article

References (33)

1. (a) Mekhail, T. M.; Markman, M. Paclitaxel in cancer therapy. Expert Opin. Pharmacother. 2002, 3, 755-766.
2. (b) Ferlini, C.; Ojima, I.; Distefano, M.; Gallo, D.; Riva, A.; Morazzoni, P.; Bombardelli, E.; Mancuso, S.; Scambia, G. Second generation taxanes: from the natural framework to the challenge of drug resistance. Curr. Med. Chem. Anti-Cancer Agents 2003, 3, 133-138.
3. Vyas, D. M.; Wong, H.; Crosswell, A. R.; Casazza, A. M.; Knipe, J. O.; Mamber, S. W.; Doyle, T. W. Synthesis and antitumor evaluation of water soluble taxol phosphates. Bioorg. Med. Chem. Lett. 1993, 3, 1357-1360.
4. Gennari, A.; Salvadori, B.; Tognoni, A.; Conte, P. F. Rapid intravenous premedication with dexamethasone prevents hypersensitivity reactions to paclitaxel. Ann. Oncol. 1996, 7, 978-979.
5. (a) Nicolau, K. C.; Riemer, C.; Kerr, M. A.; Rideout, D.; Wrasidlo, W. Design, synthesis and biological activity of protaxols. Nature 1993, 364, 464-466.
6. (b) Nicolaou, K. C.; Guy, R. K.; Pitsinos, E. N.; Wrasidlo, W. A water-soluble prodrug of taxol with self-assembling properties. Angew. Chem., Int. Ed. Engl. 1994, 33, 1583-1587.
7. (c) Seligson, A. L.; Terry, R. C.; Bressi, J. C.; Douglass, J. G., III; Sovak, M. A new prodrug of paclitaxel: synthesis of Protaxel. Anti-cancer Drugs 2001, 12, 305-313.
8. (d) Khmelnitsky, Y. L.; Budde, C.; Arnold, M. J.; Usyatinsky, A.; Clark, D. S.; Dordick, J. S. Synthesis of water-soluble paclitaxel derivatives by enzymatic acylation. J. Am. Chem. Soc. 1997, 119, 11554-11555.
9. (e) de Groot, F. M. H.; van Berkom, L. W. A.; Scheeren, H. W. Synthesis and biological evaluation of 2′-carbamate-linked and 2′-carbonate-linked prodrugs of paclitaxel: Selective activation by the tumor-associated protease plasmin. J. Med. Chem. 2000, 43, 3093-3102 and references therein.
10. (f) Bradley, M. O.; Webb, N. L.; Anthony, F. H.; Devanesan, P.; Witman, P. A.; Hemamalini, S.; Chander, M. C.; Baker, S. D.; He, L.; Horwitz, S. B.; Swindell, C. S. Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel. Clin. Cancer Res. 2001, 7, 3229-3238.
11. (g) Guillemard, V.; Saragovi, H. U. Taxane-antibody conjugates afford potent cytotoxicity, enhanced solubility, and tumor target selectivity. Cancer Res. 2001, 61, 694.
12. (h) Schmidt, F.; Ungureanu, I.; Duval, R.; Pompon, A.; Monneret, C. Cancer chemotherapy: A paclitaxel prodrug for ADEPT (antibody-directed enzyme prodrug therapy). Eur. J. Org. Chem. 2001, 11, 2129-2134.
13. (i) Safavy, A.; Raisch, K. P.; Khazaeli, M. B.; Buchsbaum, D. J.; Bonner, J. A. Paclitaxel derivatives for targeted therapy of cancer: Toward the development of smart taxanes. J. Med. Chem. 1999, 42, 4919-4924.
14. (j) Singer, J. W.; Baker, B.; De Vries, P.; Kumar, A.; Shaffer, S.; Vawter, E.; Bolton, M.; Garzone, P. Poly-(L)-glutamic acid-paclitaxel (CT-2103) [XYOTAX], a biodegradable polymeric drug conjugate: characterization, preclinical pharmacology, and preliminary clinical data. Adv. Exp. Med. Biol. 2003, 519, 81-99.
15. (k) Meerum Terwogt, J. M.; ten Bokkel Huinink, W. W.; Schellens, J. H. M.; Schot, M.; Mandjes, I. A. M.; Zurlo, M. G.; Rocchetti, M.; Rosing, H.; Koopman, F. J.; Beijnen, J. H. Phase I clinical and pharmocokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel. Anti-Cancer Drugs 2001, 12, 315-323.
16. (l) Sparreboom, A.; Wolff, A. C.; Verweij, J.; Zabelina, Y.; van Zomeren, D. M.; McIntire, G. L.; Swindell, C. S.; Donehower, R. C.; Baker, S. D. Disposition of docosahexaenoic acid-paclitaxel, a novel taxane, in blood: In vitro and clinical pharmacokinetic studies. Clin. Cancer Res. 2003, 9, 151-159.
17. (m) Wrasidlo, W.; Niethammer, A.; Deger, S.; Sehouli, J.; Kulozik, A.; Geilen, W.; Henze, G.; Gaedicke, G.; Lode, H. N. Pilot study of hydrolytically activated paclitaxel prodrug therapy in patients with progressive malignancies. Curr. Ther. Res. 2002, 63, 247-262.
18. Uoto, K.; Takenoshita, H.; Yoshino, T.; Hirota, Y.; Ando, S.; Mitsui, I. ; Terasawa, H.; Soga, T. Synthesis and evaluation of water-soluble nonprodrug analogues of docetaxel bearing secaminoethyl group at the C-10 position. Chem. Pharm. Bull. 1998, 46, 770-776.
19. Malingre, M. M.; Beijnen, J. H.; Schellens, J. H. M. Oral delivery of taxanes. Invest. New Drugs 2001, 19, 155-162.
20. Damen, E. W. P.; Nevalainen, T. J.; van den Bergh, T. J. M.; de Groot, F. M. H.; Scheeren, H. W. Synthesis of novel paclitaxel prodrugs designed for bioreductive activation in hypoxic tumour tissue. Bioorg. Med. Chem. 2002, 10, 71-77. This report expected the O-N benzoyl migration for the formation of paclitaxel, but our concept of isolated isotaxel was not considered at all.
21. Stewart J. M. Protection of the hydroxyl group in peptide synthesis. In The Peptides; Gross, E.; Meienhofer, J., Eds.; Academic Press: New York, 1981, 3, 170-201.
22. (a) Kimura, T.; Ohtake, J.; Nakata, S.; Enomoto, H.; Moriwaki, H.; Akaji, K.; Kiso, Y. Synthesis of prodrugs of HIV protease inhibitors. In Peptide Chemistry 1994; M. Ohno, Ed.; Protein Research Foundation: Osaka, 1995; pp 157-160.
23. (b) Kiso, Y.; Yamaguchi, S.; Matsumoto, H.; Kimura, T.; Akaji, K. "O, N-Acyl migration"-type prodrugs of dipeptide HIV protease inhibitors. Peptides, Frontiers of Peptide Science, Proc. 15th American Peptide Symposium; Tam, J. P.; Kaumaya, P. T. P., Eds.; Kluwer Academic: Netherlands, 1999; pp 678-679.
24. (c) Kiso, Y.; Matsumoto, H.; Yamaguchi, S.; Kimura, T. Design of small pepti-domimetic HIV-1 protease inhibitors and prodrug forms. Lett. Pept. Sci. 1999, 6, 275-281.
25. (d) Hamada, Y.; Ohtake, J.; Sohma, Y.; Kimura, T.; Hayashi, Y.; Kiso, Y. New water-soluble prodrugs of HIV protease inhibitors based on O→N intramolecular acyl migration. Bioorg. Med. Chem. 2002, 10, 4155-4167.
26. (e) Hamada, Y.; Matsumoto, H.; Kimura, T.; Hayashi, Y.; Kiso, Y. Effect of the acyl groups on O→N acyl migration in the water-soluble prodrugs of HIV-1 protease inhibitor. Bioorg. Med. Chem. Lett. 2003, 13, 2727-2730.
27. Hurley, T. R.; Colson, C. E.; Hicks, G.; Ryan, M. J. Orally active water-soluble N,O-acyl transfer products of a β, γ-bishydroxyl amide containing renin inhibitor. J. Med. Chem. 1993, 36, 1496-1498.
28. Alternatively 4 can be prepared de novo, see: (a) Palomo, C.; Arrieta, A.; Cossio, F. P.; Aizpurua, J. M.; Mielgo, A.; Aurrekoetxea, N. Highly stereoselective synthesis of α-hydroxy-β-amino acids through β-lactams: Application to the synthesis of the taxol and bestatin side chains and related system. Tetrahedron Lett. 1990, 31, 6429-6432. Mas, J.-M.; Massonneau, V. Process for preparing taxane derivatives. US Patent 5677462, 1997; Chem. Abstr. 1994, 121, 157915s.
29. Alternatively 4 can be prepared de novo, see: (a) Palomo, C.; Arrieta, A.; Cossio, F. P.; Aizpurua, J. M.; Mielgo, A.; Aurrekoetxea, N. Highly stereoselective synthesis of α-hydroxy-β-amino acids through β-lactams: Application to the synthesis of the taxol and bestatin side chains and related system. Tetrahedron Lett. 1990, 31, 6429-6432. Mas, J.-M.; Massonneau, V. Process for preparing taxane derivatives. US Patent 5677462, 1997; Chem. Abstr. 1994, 121, 157915s.
30. 7-Troc-baccatin III was prepared by conventional manner, see: (a) Damen, E. W. P.; Braamer, L.; Scheeren, H. W. Lanthanide trifluoromethanesulfonate catalysed selective acylation of 10-deacetylbaccatin III. Tetrahedron Lett. 1998, 39, 6081-6082. (b) Magri, N. F.; Kingston, D. G. I.; Jitrangsri, C.; Piccariello, T. Modified taxols. 3. Preparation and acylation of baccatin III. J. Org. Chem. 1986, 51, 3239-3242.
31. 7-Troc-baccatin III was prepared by conventional manner, see: (a) Damen, E. W. P.; Braamer, L.; Scheeren, H. W. Lanthanide trifluoromethanesulfonate catalysed selective acylation of 10-deacetylbaccatin III. Tetrahedron Lett. 1998, 39, 6081-6082. (b) Magri, N. F.; Kingston, D. G. I.; Jitrangsri, C.; Piccariello, T. Modified taxols. 3. Preparation and acylation of baccatin III. J. Org. Chem. 1986, 51, 3239-3242.
32. The utilization of oxazolidine derivatives of phenylisoserine to avoid epimerization during the esterification process has been reported, see: Didier, E.; Fouque, E.; Taillepied, I.; Commerçon, A. 2-Monosubstituted-1,3-oxazolidines as improved protective groups of N-Boc-phenylisoserine in docetaxel preparation. Tetrahedron Lett. 1994, 35, 2349-2352.
33. Singla, A. K.; Garg, A.; Aggarwal, D. Paclitaxel and its formulations. Int. J. Pharm. 2002, 235, 179-192.